Robert Young Net Worth

The estimated Net Worth of Robert C Young is at least $212 mil dollars as of 19 February 2013. Robert Young owns over 990 units of AVEO Pharmaceuticals Inc stock worth over $135,000 and over the last 19 years he sold AVEO stock worth over $0. In addition, he makes $76,860 as Independent Director at AVEO Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Robert Young AVEO stock SEC Form 4 insiders trading

Robert has made over 7 trades of the AVEO Pharmaceuticals Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 990 units of AVEO stock worth $6,534 on 19 February 2013.

The largest trade he's ever made was exercising 6,500 units of AVEO Pharmaceuticals Inc stock on 18 August 2011 worth over $48,360. On average, Robert trades about 366 units every 59 days since 2005. As of 19 February 2013 he still owns at least 9,000 units of AVEO Pharmaceuticals Inc stock.

You can see the complete history of Robert Young stock trades at the bottom of the page.

Robert Young biography

Dr. Robert C. Young M.D. serves as Independent Director of the Company. Dr. Young is president of RCY Medicine, a consulting company focused on cancer center productivity, health care quality and health policy, which he founded in July 2009. From 2007 to 2009, Dr. Young served as chancellor of Fox Chase Cancer Center, and from 1989 to 2007, as its president and chief executive officer. Dr. Young is a past president of the American Society of Clinical Oncology (ASCO), the American Cancer Society and the International Gynecologic Cancer Society, a past chairman of the board of scientific advisors of the National Cancer Institute and a past chairman of the National Comprehensive Cancer Network. Dr. Young serves on the boards of Friends of Cancer Research and NCCN Foundation, each non-profit organizations. Dr. Young is also a member of the scientific advisory boards of the Kansas Cancer Center and the Oklahoma Cancer Center. Dr. Young has also served as chairman of the editorial board of Oncology Times. Dr. Young served on the board of directors of West Pharmaceutical Services, Inc., a public pharmaceutical technology company, from July 2002 to May 2012, and on the board of directors of Human Genome Sciences, Inc., a biopharmaceutical company, from November 2005 to July 2012. Dr. Young holds a B.Sc. in zoology from The Ohio State University and an M.D. from Cornell University Medical College and is board certified in Internal Medicine, Hematology and Medical Oncology. Young’s qualifications to serve on our board of directors include his extensive leadership in cancer research as head of the Fox Chase Cancer Center, as chairman of the board of scientific advisors of the National Cancer Institute and at the National Cancer Policy Board at the Institute of Medicine; his service as a director of public life sciences companies West Pharmaceutical Services and Human Genome Sciences and his accomplished background as a board-certified physician.

What is the salary of Robert Young?

As the Independent Director of AVEO Pharmaceuticals Inc, the total compensation of Robert Young at AVEO Pharmaceuticals Inc is $76,860. There are 7 executives at AVEO Pharmaceuticals Inc getting paid more, with Michael Bailey having the highest compensation of $1,589,640.

How old is Robert Young?

Robert Young is 80, he's been the Independent Director of AVEO Pharmaceuticals Inc since 2009. There are no older and 13 younger executives at AVEO Pharmaceuticals Inc.

What's Robert Young's mailing address?

Robert's mailing address filed with the SEC is C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON, MA, 02108.

Insiders trading at AVEO Pharmaceuticals Inc

Over the last 15 years, insiders at AVEO Pharmaceuticals Inc have traded over $6,664,465 worth of AVEO Pharmaceuticals Inc stock and bought 153,034,058 units worth $217,351,881 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, AVEO Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $9,488,415. The most recent stock trade was executed by Michael P Bailey on 20 December 2022, trading 276,746 units of AVEO stock currently worth $1,248,124.

What does AVEO Pharmaceuticals Inc do?

AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO's lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO's pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO's earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.

Complete history of Robert Young stock trades at AVEO Pharmaceuticals Inc e West Pharmaceutical Services

AVEO Pharmaceuticals Inc executives and stock owners

AVEO Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Michael Bailey,
  President, Chief Executive Officer, Director
• Michael P. Bailey,
  CEO, Pres & Director
• Karuna Rubin,
  Senior Vice President, General Counsel
• Michael Needle,
  Chief Medical Officer
• Kenneth Bate,
  Lead Independent Director
• Gregory Mayes,
  Independent Director
• Anthony Evnin,
  Independent Director
• Robert Young,
  Independent Director
• Scarlett Spring,
  Independent Director
• David Pitts,
  IR Contact Officer
• Erick Lucera,
  Chief Financial Officer
• Dr. Sinai Davis M.D.,
  VP & Global Head of Pharmacovigilance
• Jeb Ledell,
  Chief Operating Officer
• Erick Lucera CFA, CPA,
  Chief Financial Officer
• Michael Ferraresso,
  Chief Commercial Officer
• Catherine DeRose,
  VP of HR
• David Crist,
  VP of Sales
• Kevin Peacock,
  VP of Marketing
• Danielle Holland,
  Sr. Corp. Counsel & Corp. Sec.
• Dr. Emile Farhan,
  Sr. VP of Technical Operations & Quality Assurance
• Lisa M. Bruneau,
  VP of Financial Accounting & Reporting and Treasurer
• Erick Lucera CPA, CFA,
  Chief Financial Officer
• Scott D Sandell,
  10% owner
• Peter W. Sonsini,
  10% owner
• Joshua Makower,
  10% owner
• Equity Opportunities Fund I...,
  
• Henri A Termeer,
  Director
• Keith S Ehrlich,
  Chief Financial Officer
• Forest Baskett,
  10% owner
• Ravi Viswanathan,
  10% owner
• Jon Sakoda,
  10% owner
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Peter J Barris,
  10% owner
• Equity Opportunities Fund I...,
  
• Matthew D Dallas,
  VP, Finance
• Nikhil Mehta,
  See Remarks
• John Johnson,
  Director
• Chetan Puttagunta,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Kevin Joseph Cullen,
  Director
• Bioventures Ii Qp Lpmpm Bio...,
  
• Douglas G. Cole,
  Director
• David Brannon Johnston,
  Chief Financial Officer
• Jeno Gyuris,
  SVP, Head of Research
• Russell C Hirsch,
  Director
• Kenneth E Weg,
  Director
• Elan Ezickson,
  Chief Business Officer
• William Slichenmyer,
  Chief Medical Officer
• Nicholas Galakatos,
  Director
• Ronald A De Pinho,
  Director
• Joseph Vittiglio,
  SVP & General Counsel
• Robert S Epstein,
  Director
• Murray O. Robinson,
  SVP, Translational Medicine
• Raju S Kucherlapati,
  Director
• Mary Ellen Jones,
  SVP, Human Resources
• Ngoc Tuan Ha,
  Chief Executive Officer
• Corinne Epperly,
  Director
• Michael Ferraresso,
  Chief Commercial Officer
• Jebediah Ledell,
  Chief Operating Officer
• Enterprise Associates 15, L...,
  10% owner
• Equity Opportunities Fund I...,
  10% owner
• Partners 15, L.P.Nea 15 Gp,...,